TNSN07200A1 - Dibenzylamines et derives - Google Patents

Dibenzylamines et derives

Info

Publication number
TNSN07200A1
TNSN07200A1 TNP2007000200A TNSN07200A TNSN07200A1 TN SN07200 A1 TNSN07200 A1 TN SN07200A1 TN P2007000200 A TNP2007000200 A TN P2007000200A TN SN07200 A TNSN07200 A TN SN07200A TN SN07200 A1 TNSN07200 A1 TN SN07200A1
Authority
TN
Tunisia
Prior art keywords
cholesterol
levels
certain
dibenzylamines
derivatives
Prior art date
Application number
TNP2007000200A
Other languages
English (en)
French (fr)
Inventor
George Chang
Mary Theresa Didiuk
Peter Hans Dorff
Ravi Shanker Garigipati
Wenhua Jiao
Bruce Allen Lefker
David Austen Perry
Roger Benjamin Ruggeri
Toby James Underwood
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN07200A1 publication Critical patent/TNSN07200A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • C07D257/06Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
TNP2007000200A 2004-11-23 2007-05-22 Dibenzylamines et derives TNSN07200A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63043404P 2004-11-23 2004-11-23
US71561705P 2005-09-12 2005-09-12
PCT/IB2005/003500 WO2006056854A1 (en) 2004-11-23 2005-11-21 Dibenzyl amine compounds and derivatives

Publications (1)

Publication Number Publication Date
TNSN07200A1 true TNSN07200A1 (fr) 2008-11-21

Family

ID=35828305

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000200A TNSN07200A1 (fr) 2004-11-23 2007-05-22 Dibenzylamines et derives

Country Status (22)

Country Link
US (1) US20090239865A1 (OSRAM)
EP (1) EP1817297A1 (OSRAM)
JP (1) JP2008520645A (OSRAM)
KR (1) KR20070069213A (OSRAM)
AP (1) AP2007003980A0 (OSRAM)
AR (1) AR053784A1 (OSRAM)
AU (1) AU2005308584A1 (OSRAM)
BR (1) BRPI0518476A2 (OSRAM)
CA (1) CA2589322A1 (OSRAM)
CR (1) CR9089A (OSRAM)
EA (1) EA200700924A1 (OSRAM)
GT (1) GT200500339A (OSRAM)
IL (1) IL183133A0 (OSRAM)
MA (1) MA29039B1 (OSRAM)
MX (1) MX2007006137A (OSRAM)
NL (1) NL1030486C2 (OSRAM)
NO (1) NO20073025L (OSRAM)
PE (1) PE20061124A1 (OSRAM)
TN (1) TNSN07200A1 (OSRAM)
TW (1) TW200630350A (OSRAM)
UY (1) UY29222A1 (OSRAM)
WO (1) WO2006056854A1 (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103102303B (zh) 2004-12-31 2015-10-28 雷迪博士实验室有限公司 作为cetp抑制剂的苄胺衍生物
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2007041494A2 (en) * 2005-09-30 2007-04-12 Merck & Co., Inc. Cholesteryl ester transfer protein inhibitors
EP1981342B1 (en) * 2005-12-28 2016-11-30 Dr. Reddy's Laboratories Ltd. Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
KR20080086917A (ko) * 2005-12-29 2008-09-26 노파르티스 아게 콜레스테릴 에스테르 전달 단백질 (cetp) 억제제로서의피리디닐 아민 유도체
PE20071025A1 (es) * 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
MX2008014284A (es) 2006-05-10 2008-11-18 Novartis Ag Derivados biciclicos como inhibidores de cetp.
US20090181929A1 (en) * 2006-05-11 2009-07-16 Kazuhide Konishi Organic compounds
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
HUE024898T2 (en) 2007-04-13 2016-02-29 Kowa Co New pyrimidine compound with dibenzylamine structure and drug containing compound
JP4846769B2 (ja) * 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
JP4834699B2 (ja) * 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
EP2222639A1 (en) * 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
EP2222638A2 (en) * 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating inflammation
UA98839C2 (en) * 2008-02-01 2012-06-25 Панмира Фармасьютикалз, Ллк. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2009099902A1 (en) 2008-02-01 2009-08-13 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
JP2011512359A (ja) 2008-02-14 2011-04-21 アミラ ファーマシューティカルズ,インク. プロスタグランジンd2受容体のアンタゴニストとしての環式ジアリールエーテル化合物
WO2009108720A2 (en) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
JP2011518130A (ja) 2008-04-02 2011-06-23 アミラ ファーマシューティカルズ,インク. プロスタグランジンd2受容体のアミノアルキルフェニルアンタゴニスト
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) * 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
WO2010059838A2 (en) * 2008-11-20 2010-05-27 Decode Genetics Ehf Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects
SG10201404662YA (en) 2009-08-05 2014-10-30 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
AU2011203649A1 (en) 2010-01-06 2012-06-14 Brickell Biotech, Inc. DP2 antagonist and uses thereof
WO2012030165A2 (ko) 2010-08-31 2012-03-08 서울대학교산학협력단 P P A R δ 활성물질의 태자재프로그래밍용도
SG10201605304VA (en) 2011-07-08 2016-08-30 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
EP2744803A2 (en) 2011-08-18 2014-06-25 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
AU2012313971B2 (en) 2011-09-27 2016-09-29 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis
WO2014099836A1 (en) 2012-12-19 2014-06-26 Merck Sharp & Dohme Corp. Spirocyclic cetp inhibitors
CN112074505B (zh) 2018-03-08 2024-04-05 因赛特公司 作为PI3K-γ抑制剂的氨基吡嗪二醇化合物
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN115677572B (zh) * 2021-07-29 2024-05-28 武汉思瓴生物科技有限公司 氟代酰胺类衍生物、药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064549A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
JP2003221376A (ja) * 2001-11-21 2003-08-05 Japan Tobacco Inc Cetp活性阻害剤
US6653334B1 (en) * 2002-12-27 2003-11-25 Kowa Co., Ltd. Benzoxazole compound and pharmaceutical composition containing the same
CN1942428A (zh) * 2004-04-13 2007-04-04 默克公司 Cetp抑制剂

Also Published As

Publication number Publication date
AP2007003980A0 (en) 2007-06-30
AR053784A1 (es) 2007-05-23
BRPI0518476A2 (pt) 2008-11-18
GT200500339A (es) 2006-06-22
JP2008520645A (ja) 2008-06-19
KR20070069213A (ko) 2007-07-02
MA29039B1 (fr) 2007-11-01
CR9089A (es) 2007-05-30
MX2007006137A (es) 2007-07-19
NO20073025L (no) 2007-08-20
NL1030486A1 (nl) 2006-05-24
AU2005308584A1 (en) 2006-06-01
CA2589322A1 (en) 2006-06-01
IL183133A0 (en) 2007-09-20
EA200700924A1 (ru) 2007-10-26
EP1817297A1 (en) 2007-08-15
UY29222A1 (es) 2006-06-30
PE20061124A1 (es) 2006-10-13
TW200630350A (en) 2006-09-01
US20090239865A1 (en) 2009-09-24
NL1030486C2 (nl) 2006-10-24
WO2006056854A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
TNSN07200A1 (fr) Dibenzylamines et derives
MA30272B1 (fr) Derives de dibenzylamines servant d'inhibiteurs de cetp.
MA27532A1 (fr) Piperidines a substituant phenyle, destinees a etre utilisees comme activateurs de ppar
TNSN06447A1 (fr) Composes heteroaryle et phenylsulfamoyle substitues
TNSN07100A1 (fr) Derives de 1, 2, 3, 4- tetrahydroquinoleine substitues en position 2 et a substituant 4-amino
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
BRPI0508584A (pt) lipìdio estruturado contendo composições e métodos com caracterìsticas promotoras de saúde e nutrição
ATE514345T1 (de) Zusammensetzung zur senkung des blutcholesterolspiegels
TNSN04164A1 (fr) Inhibiteurs de acc.
MY130670A (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
MA27728A1 (fr) Antagonistes des recepteurs de cgrp
BR9904162A (pt) 4-carboxiamino-2-metil-1,2,3,4-tetra-hidroquinolinas aneladas
PL405074A1 (pl) Zastosowanie alpha-cyklodrkstryny do wytwarzania leku do obnizenia poziomów trójglicerydów
MA27427A1 (fr) Composes de benzimidazole-1-yl-thiophene utilises en cancerotherapie
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
MA32131B1 (fr) Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine
MY121405A (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
ATE332887T1 (de) Naturstoffe und deren derivate zur prävention und behandlung von herzkreislauf-, leber- und nierenerkrankungen und für kosmetische anwendungen
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MXPA05012570A (es) Derivados de tetrahidroisoquinolina como activadores de ppar-a.
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
MA30271B1 (fr) Dibenzylamines et derives
TN2009000483A1 (fr) Derives de 7-alkynyl-1-8-naphthyridones, leur preparation et leur application en therapeutique